|Brief Description||Principal Investigator|
The primary objectives are as follows:
To evaluate the safety, tolerability, and dose-limiting toxicities (DLTs) of AGEN1884 in subjects with advanced or metastatic cancer (solid tumors or lymphoma) including but not limited to carcinoma, sarcoma, malignant glioma, or melanoma.
To determine the maximum tolerated dose (MTD).
To evaluate the pharmacokinetics (PK) of AGEN1884 in subjects with advanced or
metastatic solid tumors.
|Hwang, Jimmy John|
|To describe the anti-tumor activity (efficacy) and toxicity (safety) of commercially available, targeted anti-cancer drugs used for treatment of patients with advanced solid tumors, multiple myeloma or B cell non-Hodgkin lymphoma with a genomic variant known (i) to be a target of an FDA-approved anti-cancer drug or (ii) to predict sensitivity to an FDA-approved anti-cancer drug.||Kim, Edward Sanghyun|
|To investigate the safety and tolerability of selumetinib when given in combination with MEDI4736 to patients with advanced solid malignancies.||Kim, Edward Sanghyun|
I. To maintain a Childhood Cancer Registry for infants, children, adolescents, and young adults with cancer.
II. To utilize clinical and biological data to help determine eligibility or stratification, based on childhood cancer disease classification schemas, for potential enrollment of research subjects onto Children's Oncology Group (COG) therapeutic clinical trials.
III. To develop a well annotated childhood cancer biobank for current and future research through the collection of biospe
|Kaplan, Joel Adam|
|To assess the safety and tolerability of escalating doses of SD-101 in combination with pembrolizumab in patients with metastatic melanoma. To evaluate the pharmacodynamic (PD) profile of interferon (IFN) inducible genes in whole blood 24 hours after intratumoral injection of SD-101 during pembrolizumab therapy. To determine the Maximum Tolerated Dose (MTD) or Optimal Dose of intratumoral SD-101 in combination with pembrolizumab.||Amin, Asim|
|The purpose of this registry is to collect information on patients who are receiving treatment with Proleukin in an organized way, and to learn more about patient care during and after treatment.||Amin, Asim|